Antibody-Drug Conjugates for Cancer Treatment

Annual Review of Medicine

Volumn 69, Issue , 2018, Pages 191-207

  Lambert, John M ^a   Berkenblit, Anna ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

ADC; Antibody drug conjugate; Cytotoxic payload; Monoclonal antibody; Targeted drug delivery

Indexed keywords

ANETUMAB RAVTANSINE; ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; MIRVETUXIMAB SORAVTANSINE; ROVALPITUZUMAB TESIRINE; TRASTUZUMAB EMTANSINE; VADASTUXIMAB TALIRINE; ANTIBODY CONJUGATE; MAYTANSINE; TRASTUZUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG SYNTHESIS; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SOLID MALIGNANT NEOPLASM; ANAPLASTIC LARGE CELL LYMPHOMA; BREAST TUMOR; DRUG DEVELOPMENT; HODGKIN DISEASE; METABOLISM; NEOPLASM;

BREAST NEOPLASMS; DRUG DEVELOPMENT; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MAYTANSINE; NEOPLASMS; TRASTUZUMAB;

EID: 85041706593     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-061516-121357     Document Type: Article

References (101)

1. Miller DR. 2006. A tribute to Sidney Farber\-The father of modern chemotherapy. Br. J. Haematol. 134:20-26
2. Frei E III. 1972. Combination cancer therapy: presidential address. Cancer Res. 32:2593-607
3. Chari RV, Miller ML, WiddisonWC. 2014. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem. Int. Ed. 53:3796-827
4. Issel BF, Crooke ST. 1978. Maytansine. Cancer Treat. Rev. 5:199-207
5. Cristofanilli M, Bryan WJ, Miller LL, et al. 1998. Phase II study of adozelesin in untreated metastatic breast cancer. Anticancer Drugs 9:779-82
6. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-97
7. Lambert JM. 2017. Typical antibody-drug conjugates. In Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer, ed. KJ Olivier Jr., SA Hurvitz, pp. 3-32. Hoboken, NJ:Wiley
8. Senter PD, Sievers EL. 2012. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30:631-37
9. Lambert JM, Chari RV. 2014. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J. Med. Chem. 57:6949-64
10. Beck A, Goetsch L, Dumontet C, et al. 2017. Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 16:315-37
11. Starling JJ, Maciak RS, Law KL, et al. 1991. In vivo antitumor activity of a monoclonal antibodyvinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes. Cancer Res. 51:2965-72
12. Trail PA,Willner D, Lasch SJ, et al. 1993. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212-15
13. Petersen BH, DeHerdt SV, Schneck DW, et al. 1991. The immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 51:2286-90
14. Tolcher AW. 2000. BR96-doxorubicin: been there, done that! J. Clin. Oncol. 18:4000
15. Thurber GM, Schmidt MM, Wittrup KD. 2008. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60:1421-34
16. McLarty K, Cornelissen B, Scollard DA, et al. 2009. Associations between the uptake of 111In-DTPAtrastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumor xenografts. Eur. J. Nucl. Med. Mol. Imag. 36:81-93
17. Sedlacek H-H, Seemann G, Hoffmann D, et al. 1992. Antibodies as carriers of cytotoxicity. In Contributions to Oncology, ed. H Huber,WQueisser, 43:1-145. Basel, Switz.: Karger
18. Hudziak RM, Lewis GD, Winget M, et al. 1989. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell Biol. 9:1165-72
19. Adams GP, Schier R, McCall AM, et al. 2001. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. Cancer Res. 61:4750-55
20. Doronina SO,Toki BE, Torgov MY, et al. 2003. Development of potentmonoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21:778-84
21. Widdison WC, Wilhelm SD, Cavanagh EE, et al. 2006. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 49:4392-408
22. Smith AL, Nicolaou KC. 1996. The enediyne antibiotics. J. Med. Chem. 39:2103-17
23. Elgersma RC, Coumans RG, Huijbregts T, et al. 2015. Design, synthesis, and evaluation of linkerduocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985. Mol. Pharm. 12:1813-35 www.annualreviews.org Antibody-Drug Conjugates 203
24. Kung Sutherland MS, Walter RB, Jeffrey SC, et al. 2013. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active inmodels of drug-resistant AML. Blood 122:1455-63
25. Miller ML, Fishkin NE, Li W, et al. 2016. A new class of antibody-drug conjugates with potent DNA alkylating activity. Mol. Cancer Ther. 15:1870-78
26. Senter PD. 2009. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 13:235-44
27. Singh R, Lambert JM, Chari RV. 2014. Antibody-drug conjugates: new frontier in cancer therapeutics. In Handbook of Therapeutic Antibodies, ed. S Dübel, JM Reichert, pp. 341-62. Hoboken, NJ: Wiley. 2nd ed.
28. Erickson HK, Park PU,WiddisonWC, et al. 2006. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66:4426-33
29. Doronina SO, Mendelsohn BA, Bovee TD, et al. 2006. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17:114-24
30. Lai KC, Deckert J, Setiady YY, et al. 2015. Evaluation of targets for maytansinoid ADC therapy using a novel radiochemical assay. Pharm. Res. 32:3593-603
31. Kovtun YV, Audette CA, Ye Y, et al. 2006. Antibody-drug conjugates designed to eradicate tumor with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66:3214-21
32. Polson AG, Calemine-Fenaux J, Chan P, et al. 2009. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 69:2358-64
33. WiddisonWC, Ponte JF, Coccia JA, et al. 2015. Development of anilino-maytansinoid ADCs that efficiently release cytotoxic metabolites in cancer cells and induce high levels of bystander killing. Bioconjug. Chem. 26:2261-78
34. Zhao RY, Wilhelm SD, Audette C, et al. 2011. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J. Med. Chem. 54:3606-23
35. Kovtun YV, Audette CA, Mayo MF, et al. 2010. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 70:2528-37
36. Hong EE, EricksonH,LutzRJ, et al. 2015. Design of coltuximab ravtansine, a CD19-targeting antibodydrug conjugate (ADC) for the treatment of B-cell malignancies: structure-activity relationships and preclinical evaluation. Mol. Pharm. 12:1703-16
37. Sun X, Ponte JF, Yoder NC, et al. 2017. Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug. Chem. 28:1371-81
38. Liu JF, Moore KN, Wang JS, et al. 2017. Targeting MUC16 with the THIOMABTM-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a phase I escalation study. Am. Assoc. Cancer Res. Annu. Meet. Abstr. CT009
39. Stein AS, Walter RB, Erba HP, et al. 2015. A phase I trial of SGN-CD33A as monotherapy in patients with CD33-positive acute myeloid leukemia (AML). Am. Soc. Hematol. Annu. Meet. Abstr. 324
40. Sharkey RM, Goldenberg DM. 2008. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv. Drug Delivery Rev. 60:1407-20
41. Sievers EL, Larson RA, Stadtmauer EA, et al. 2001. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19:3244-54
42. Bross PF, Beitz J, Chen G, et al. 2001. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7:1490-96
43. Giles FJ, Kantarjian HM, Kornblau SM, et al. 2001. MylotargTM (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92:406-13
44. Petersdorf SH, Kopecky KJ, Slovak M, et al. 2013. A phase 3 study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia. Blood 121:4854-60
45. Hills RK, Castaigne S, Appelbaum FR, et al. 2014. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomized controlled trials. Lancet Oncol. 15:986-96
46. Younes A, Gopal AK, Smith SE, et al. 2012. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodkgin's lymphoma. J. Clin. Oncol. 30:2183-89
47. Pro B, Advani R, Brice P, et al. 2012. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30:2190-96
48. Younes A, Bartlett NL, Leonard JP, et al. 2010. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363:1812-21
49. MoskowitzCH, Nademanee A,MassziT, et al. 2015. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853-62
50. Prince HM, Kim YH, Horwitz SM, et al. 2017. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomized, phase 3, multicenter trial. Lancet 17:31266-67
51. DiJoseph JF, Armellino DC, Boghaert ER, et al. 2004. Antibody-targeted chemotherapy with CMC-544: aCD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoidmalignancies. Blood 103:1807-14
52. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. 2016. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375:740-53
53. GuffroyM, Falahatpisheh H, Biddle K, et al. 2017. Liver microvascular injury and thrombocytopenia of antibody-calicheamicin conjugates in cynomolgus monkeys-mechanism and monitoring. Clin. Cancer Res. 23:1760-70
54. Godwin CD, McDonald GB, Walter RB. 2017. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood 129:2330-32
55. Fathi AT, Erba HP, Lancet JE, et al. 2016. Vadastuximab talirine plus hypomethylating agents: a welltolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML). Am. Soc. Hematol. Annu. Meet. Abstr. 591
56. Hochhauser D, Meyer T, Spanswick VJ, et al. 2009. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin. Cancer Res. 15:2140-47
57. Verma S, Miles D, Gianni L, et al. 2012. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367:1783-91
58. Krop IE, Beeram M, Modi S, et al. 2010. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28:2698-704
59. Burris HA III, Rugo HS, Vukelja SJ, et al. 2011. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29:398-405
60. Krop IE, LoRusso P, Miller KD, et al. 2012. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positivemetastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30:3234-41
61. Lambert JM, Morris CQ. 2017. Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review. Adv. Ther. 34:1015-35
62. Krop IE, Kim S-B, González-Martin A, et al. 2014. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, openlable, phase 3 trial. Lancet Oncol. 15:689-99
63. Carlson RM. 2016. TH3RESA trial: in advanced HER2+ breast cancer overall survival with T-DM1 beats "physician's choice." Oncol. Times 38:32-33
64. Perez EA, Barrios C, Eiermann W, et al. 2016. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J. Clin. Oncol. 35:141-48
65. Hurvitz SA, Dirix L, Kocsis J, et al. 2013. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patientswith human epidermal growth factor receptor 2-positivemetastatic breast cancer. J. Clin. Oncol. 31:1157-63 www.annualreviews.org Antibody-Drug Conjugates 205
66. Miller KD, Diéras V, Harbeck N, et al. 2014. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J. Clin. Oncol. 32:1437-44
67. Lewis Phillips GD, Fields CT, Li G, et al. 2014. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin. Cancer Res. 20:456-68
68. Golfier S, Kopitz C, Kahnert A, et al. 2014. Anetumab ravtansine: a novel mesothelin-targeting antibodydrug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol. Cancer Ther. 13:1537-48
69. Blumenschein GR, Hassan R, Moore KN, et al. 2016. Phase I study of anti-mesothelin antibody-drug conjugate anetumab ravtansine (AR). Am. Soc. Clin. Oncol. Meet. Abstr. 2509
70. Hassan R, Bendell JC, Blumenschein G Jr., et al. 2015. Phase I study of anti-mesothelin antibody-drug conjugate anetumab ravtansine (BAY 94-9394). Presentation No. 1574, World Conf. Lung Cancer, 16th, Denver, CO
71. Hassan R, Jennens R, van Meerbeeck JP, et al. 2016. A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or pleural metastatic mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). Am. Soc. Clin. Oncol. Meet. Abstr. TPS8576
72. Ab O, Whiteman KR, Bartle LM, et al. 2015. IMGN853, a folate receptor-α(FRα)-targeting antibodydrug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol. Cancer Ther. 14:1605-13
73. Moore KN, Borghaei H, O'Malley DM, et al. 2017. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. Cancer 123:3080-87
74. Ribrag V, Dupuis J, Tilly H, et al. 2014. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/ refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 20:213-20
75. Moskowitz CH, Fanale MA, Shah BD, et al. 2015. A phase I study of denintuzumab mafadotin (SGNCD19A) in relapsed/refractory B-lineage non-Hodgkin lymphoma. Am. Soc. Hematol. Annu. Meet. Abstr. 182
76. IbrahimNK, DesaiN,Legha S, et al. 2002. Phase 1 and pharmacokinetic study of ABI-007, aCremophorfree, protein stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8:1038-44
77. Moore KN, Martin LP, O'Malley DM, et al. 2017. Safety and activity of mirevetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian cancer, fallopian tube, or primary peritoneal cancer: a phase 1 expansion study. J. Clin. Oncol. 35:1112-18
78. Moore KN, Matulonis UA, O'Malley DM, et al. 2017. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): activity and safety analysis in phase I pooled expansion cohorts. Am. Soc. Clin. Oncol. Meet. Abstr. 5547
79. Gunderson CC, Moore KN. 2016. Mirvetuximab soravtansine: FRα-targeting ADC treatment of epithelial ovarian cancer. Drugs Future 41:539-45
80. Moore KN, Vergote I, Oaknin A, et al. 2017. FORWARD I (GOG 3011): a randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary periotoneal cancer, or primary fallopian tube cancer. Am. Soc. Clin. Oncol. Meet. Abstr. TPS5607
81. Saunders LR, Bankovich AJ, Anderson WC, et al. 2015. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 7(302):302ra136
82. Rudin CM, Pietanza MC, Bauer TM, et al. 2017. Rovalpituzumab tesirine, a DLL3-targeted antibodydrug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 18:42-51
83. Simos D, Sajjady G, Sergi M, et al. 2014. Third-line chemotherapy in small-cell lung cancer: an international analysis. Clin. Lung Cancer 15:110-18
84. O'Malley DM, Moore KN, Vergote I, et al. 2017. Safety findings from FORWARD II: a phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer. Am. Soc. Clin. Oncol. Meet. Abstr. 5553
85. Müller P,Martin K, Theurich S, et al. 2014. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol. Res. 2:741-55
86. Martin K, Müller P, Schreiner J, et al. 2014. The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol. Immunother. 63:925-38
87. Martin K, Schreiner J, Zippelius A. 2015. Modulation of APC function and anti-tumor immunity by anti-cancer drugs. Front. Immunol. 6:501
88. Müller P, Kreuzaler M, Khan T, et al. 2015. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med. 7(315):315ra188
89. Rio-Doria J,Harper J,Rothstein R, et al. 2017. Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 77:2686-98
90. Lyon RP, Bovee TD, Doronina SO, et al. 2015. Reducing hydrophobicity of homogeneous antibodydrug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33:733-35
91. Dornan D, Bennett F, Chen Y, et al. 2009. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114:2721-29
92. Deckert J, Park PU, Chicklas S, et al. 2013. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 122:3500-10
93. Schönfeld K, Zuber C, Pinkas J, et al. 2017. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J. Hematol. Oncol. 10:13
94. Bardia A, Mayer IA, Diamond JR, et al. 2017. Efficacy and safety of any-Trop-2 antibody-drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 35:2141-48
95. Yardley DA, Weaver R, Melisko ME, et al. 2015.EMERGE:a randomized phase II study of the antibodydrug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J. Clin. Oncol. 33:1609-19
96. Phillips AC, Boghaert ER, Vaidya KS, et al. 2016. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol. Cancer Ther. 15:661-69
97. Donate F, Raitano A, Morrison K, et al. 2016. AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma. Clin. Cancer Res. 22:1989-99
98. Gomez-Roca CA, Boni V, Moreno V, et al. 2016. A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870). Am. Soc. Clin. Oncol. Meet. Abstr. 2511
99. DiPippo VA, Olson WC, Nguyen HM, et al. 2015. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. Prostate 75:303-13
100. Jones TD, Carter PJ, Pl ückthun A, et al. 2016. The INNs and outs of antibody nonproprietary names. MABS 8:1-9
101. Ponte JF, Ab O, Lanieri L, et al. 2016. Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia 18:775-84